In summary, adverse drug reactions (ADRs) induced by SGLT2 inhibitors are mainly concentrated in infections and disturbances, laboratory tests, and reproductive and breast diseases, specifically manifesting as urinary and reproductive system inflammation-related conditions, such as orchitis and testicular abscess, which is consistent with the information in the FDA label. Here, SLC5A2 is linked to breast disorder.